Clinical Trial

Cambiotics initiates first human clinical trial focused on PFAS reduction in firefighters with occupational PFAS exposure

COPENHAGEN, Denmark, Nov. 3, 2026 /PRNewswire/ — Cambiotics ApS (“Cambiotics”), the company developing beneficial bacteria designed to support the natural elimination of unwanted compounds, such as per- and polyfluoroalkyl substances (PFAS, known as “forever chemicals”), announced today…

Source: Read More